Acute Ischemic Stroke and Heparin Treatments

• References

• 1 Sherman DG, Dyken ML, Gent M, Harrison MJG, Hart G, Mohr JP. Antithrombotic therapy for cerebrovascular disorders. An update. Chest 1995; 108 (Suppl. 04) 444S-456S
• 2 Ernst E. Fibrinogen : an important risk factor for atherothrombotic diseases. Ann Med 1994; 26: 15-22
• 3 Rabbani LE, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis 1994; 105: 01-07
• 4 Hamsten A, de FaireU, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma : risk factor for recurrent myocardial infarction. Lancet 1987; 02: 03-09
• 5 Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Grilli M, Simone P, Panico S, Mancini M. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994; 14: 1741-1745
• 6 Wahlberg TB, Blombäck M. Overmark-I Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease. Acta Med Scand 1980; 207: 385-390
• 7 Catto AJ, Carter AM, Barrett JH, Boothby M, Bamford J, Grant PJ. Elevated von Willebrand factor (vWf): an independent risk factor for cerebrovascular mortality. Blood Coagul Fibrinol 1995; 06: 590 (abst)
• 8 Lowe GDO. Acute stroke. In: Disorders of thrombosis. Hull R, Pineo GF. eds. WB Saunders Company; Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: 1996. pp 116-134
• 9 Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943
• 10 Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender specific associations of the fibrinogen Bβ 448 polymorphism, fibrinogen levels and acute cerebrovascular disease. Arterioscler Thromb Vase Biol. (in press)
• 11 Takano K, Yamaguchi T, Okada Y, Uchida K, Kisiel W, Kato H. Hypercoagulability in acute ischemic stroke : analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method. Thromb Res 1990; 58: 481-491
• 12 Hoffman Cj, Miller RH, Lawson WE, Hutlin MB. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol 1989; 14: 941-946
• 13 Meade TW. Haemostatic function and arterial disease. Brit Med Bull 1994; 50 (04) 755-775
• 14 ECAT Angina pectoris study group. Baseline associations of hemostatic factor with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 08-17
• 15 Catto AJ, Carter AM, Stickland MH, Bamford J, Davies JA, Grant PJ. Elevated levels of plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and the development of atherothrombotic and hemorrhagic stroke. Thromb Haemostas 1995; 74: 1399 (abst.)
• 16 Sandset PM, Andersson TR. Coagulation inhibitor levels in pneumonia and stroke : changes due to consumption and acute phase reaction. J Intern Med 1989; 225: 311-316
• 17 Koudstaal PJ, Ciabattoni G, Van GijnJ, Nieuwenhuis K, De GrootPG, Sixma JJ, Patrono C. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke 1993; 24: 219-223
• 18 Van Kooten F, Ciabattoni G, Patrono C, Schmitz PIM, Van GijnJ, Koudstaal PJ. Evidence for episodic platelet activation in acute ischemic stroke activation. Stroke 1994; 25: 278-281
• 19 D’Erasmo E, Aliberti G, Celi FS, Romagnoli E, Vecci F, Mazzuoli GF. Platelet count, mean platelet volume and their relation to prognosis in cerebral infarction. J Intern Med 1990; 227: 11-14
• 20 Bauer KA, Rosenberg RD. Activation markers of coagulation. Baillières Clin Haematol 1994; 07: 523-540
• 21 Fon EA, Mackey A, Cote R, Wolfson C, Mcilraith DM, Leclerc J, Bourque F. Hemostatic markers in acute transient ischemic attacks. Stroke 1994; 25: 282-286
• 22 Hart RG, Kanter MC. Hematologic disorders and ischemic stroke. Stroke 1990; 21: 1111-1121
• 23 Brey RL. Antiphospholipid antibodies and ischemic stroke. Heart Disease and Stroke 1992; 01: 379-382
• 24 Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity clotting factors, and long term incidence of ischemic heart disease with Northwick Park Heart Study. Lancet 1993; 342: 1076-1079
• 25 Glueck CJ, Rorick MH, Schmerler M, Anthony J, Feibel J, Bashir M, Glueck HI, Stroop D, Wang Y, Tracy TM. Hypofibrinolytic and atherogenic risk factors for stroke. J Lab Clin Med 1995; 125: 319-325
• 26 Palareti G, Legnani C, Coccheri S. Hyperhomocysteinemia and vascular disease. In « Hypercoagulable states ». Segathchian MJ, Samama MM, Hecker SP. Eds CRC Press; Boca Raton, New York, London, Tokyo: 1996. pp 395-408
• 27 Marsh III EE, Adams Jr HP, Biller J, Wasek P, Banwart K, Mitchell V, Woo IsonR. Use of antithrombotic drugs in the treatment of acute ischemic stroke. A survey of neurologists in practice in the United States. Neurology 1989; 39: 1631-1634
• 28 Sandercock PAG, Van DenBelt AGM, Lindley RI, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993; 56: 17-25
• 29 Counsell C, Sandercock P. The efficacy and safety of anticoagulant therapy in patients with acute presumed ischaemic stroke: a systematic review of the randomised trials comparing anticoagulants with control. In: Warlow C, Van GijnJ, Sandercock P. (eds) Stroke Module of The Cochrane Database of Systematic Reviews 1996. The Cochrane Collaboration, Issue 1, Oxford; Update software 1997
• 30 McCarthy ST, Turner JJ, Robertson D, Hawkey CJ, Macey DJ. Low dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1977; 02: 800-801
• 31 Eriksson SE, Link H. Evaluation of anticoagulants in patients with cerebral infarction with slight to moderate neurological deficit Acta Neurol Scand. 1983; 68: 96-106
• 32 Duke RJ, Turpie AG, Bloch RF, Trebilcock RG. Clinical trial of low dose subcutaneous heparin for the prevention of stroke progression: natural history of acute partial stroke and stroke in evolution. In Reivich M, Hurtig HI. Eds « Cerebrovascular Diseases ». New York: Raven Press; 1983. pp 399-405
• 33 Dobkin BH. Heparin for lacunar stroke in progression. Stroke 1983; 14: 421-423
• 34 Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke. A randomized trial. Stroke 1983; 14: 668
• 35 Ramirez-Lassepas M, Quinones MR, Nino HH. Treatment of acute ischemic stroke. Open trial with continuous intravenous heparinization. Arch Neurol 1986; 43: 386-390
• 36 McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age and Ageing 1986; 15: 84-88
• 37 Duke RJ, Bloch RF, Turpie AGG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke : a randomized controlled trial. Ann Intern Med 1986; 105: 825-828
• 38 Haley Jr EC, Kassel NF, Torner JC. Failure of heparin to prevent progression in progressing ischemic infarction. Stroke 1988; 19: 10-14
• 39 Jonas S. Anticoagulant therapy in cerebro-vascular disease: review and meta-analysis. Stroke 1988; 19: 1043-1048
• 40 Kay R, Wong KS, YU YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A, Woo J. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588-1593
• 41 Prins MH, Gelsema R, Sing AK, Van HeerdeLR, Den OttolanderGJH. Prophylaxis of deep venous thrombosis with a low molecular weight heparin (Kabi 2165/Fragmin®) in stroke patients. Haemostasis 1989; 19: 245-250
• 42 Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep vein thrombosis in acute ischemic stroke. Semin Thromb Hemost 1990; 16 (suppl.) 25-33
• 43 Elias A, Milandre L, Lagrange G, Aillaud MF, Alonzo B, Toulemonde F, Juhan-Vague I, Khalil R, Bayrou B, Serradimigni A. Prvéntion des thromboses veineuses profondes des membres inférieurs par une fraction d’héparine detrèsbas poids moléculaire (CY 222) chez des patients porteurs d’une hémiplégie secondaire à un infarctus cérébral : étude pilote randomisée (30 patients). La Revue de Médecine Interne 1990; 11: 95-98
• 44 Turpie AGG, Hirsh J, Jay RM, Andrew M, Hull RD, Levine MN, Carter CJ, Powers PJ, Magnani HN, Gent M. Doubleblind randomised trial of ORG 10172 low molecular weight heparinoïd in prevention of deep vein thrombosis in thrombotic stroke. Lancet 1987; 01: 523-526
• 45 Turpie AGG, Gent M, Cote R, Levine MN, Ginsberg JS, Powers PJ, Leclerc J, Geerts W, Jay R, Neemeh J, Klimek M, Hirsh J-A. low molecular weight heparinoïd compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med 1992; 117: 353-357
• 46 Yanosaki M, Uchiyama S, Maruyama S. Alterations of hemostatic markers in various subtypes and phases of stroke. Blood Coagulation and Fibrinolysis 1993; 04: 707-712
• 47 Caplan LR. To heparinize or not: an unsettled issue (letter). Stroke 1989; 20: 968
• 48 Biller J, Love BB, Gordon DL. Antithrombotic therapy for ischemic cerebrovascular disease. Semin Neurol 1991; 11: 353-367
• 49 Mahagne MH. Le traitement anticoagulant a la phase aiguë de l’infarctus cérébral. S T V 1996; 08: 567-573
• 50 Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 912-920
• 51 Nurmohamed MT, Rosendaal FR, Buller HR. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery : a meta-analysis. Lancet 1992; 02: 152-156
• 52 Adams Jr HP, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA, Feinberg W, Mayberg M. Guidelines for the management of patients with acute ischemic stroke. A statement for health care professionals. From a special writing group of the Stroke Council American Heart Association Stroke 1994; 25: 1901-1914
• 53 Bloom JM. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1996; 334: 1407 (letter)
• 54 Cosmi B, Fredenburg JC, Rischke J, Hirsh J, Young E, Weitz JI. Effect of non specific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low molecular weight heparin and dermatan sulfate. Circulation 1997; 95: 118-124